Algorithm measures quality of gait through smart watches, could help reduce falls SciReports
The percentage of walks of less than 7 s and 60 s were extracted. Total minutes of running per day was obtained through the activity classification process.
Stage 2: test–retest reliability and convergent validity of the digital gait biomarkers with respect to self-reported walking pace and healthParticipants for stage 2 comprised 78,822 participants from the UK biobank. Participants were instructed to wear an AX3 data logger over their dominant wrist for seven days in 2013. They aged 46–77 years . Ethical approval for UKBiobank data transfer and analysis was obtained from the NHS National Research Ethics Service .
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Work to start on big new housing site in Telford next year - report to councillorsA major housing development is due to get underway in Telford next year, a report to council leaders says.
Læs mere »
Oral Tau Aggregation Inhibitor for Alzheimer’s Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate - The Journal of Prevention of Alzheimer's DiseaseBackground Hydromethylthionine mesylate is a tau aggregation inhibitor shown to have exposure-dependent pharmacological activity on cognitive decline and brain atrophy in two completed Phase 3 trials in mild/moderate Alzheimer’s disease (AD). Objectives The present report summarises the basis for selection of 16 mg/day as monotherapy as the optimal treatment regime and the design rationale of a confirmatory Phase 3 trial (LUCIDITY). Design The trial comprises a 12-month double-blind, placebo-controlled phase followed by a 12-month modified delayed-start open-label treatment phase. Setting 76 clinical research sites in North America and Europe. Participants 545 patients with probable AD or MCI-AD in the final version of the protocol. Intervention Participants were assigned randomly to receive hydromethylthione mesylate at doses of 16 mg/day, 8 mg/day or placebo at a 4:1:4 ratio during the double-blind phase. All participants in the open-label phase receive the 16 mg/day dose. Measurements Co-primary clinical outcomes are the 11-item Alzheimer’s Disease Assessment Scale (ADAS-cog11) and the 23-item Alzheimer’s Disease Cooperative Study — Activities of Daily Living (ADCS-ADL23). Secondary biomarker measures include whole-brain atrophy and temporal lobe 18F-fluorodeoxyglucose positron emission tomography. Results 446 participants are expected to complete the 12-month placebo-controlled phase in March 2022. Conclusions If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. As low-dose oral hydromethylthionine mesylate is simple to use clinically, does not cause amyloid-related imaging abnormalities and has a benign safety profile, it would likely improve AD management.
Læs mere »
Tau isoform-specific enhancement of L-type calcium current and augmentation of afterhyperpolarization in rat hippocampal neurons - Scientific ReportsScientific Reports - Tau isoform-specific enhancement of L-type calcium current and augmentation of afterhyperpolarization in rat hippocampal neurons
Læs mere »
Microgel Encourages Bone Regeneration in Critical-Size DefectsAn article published in Scientific Reports demonstrated an easy method to prepare vascularized constructs based on microgels that promoted human mesenchymal stromal cell (MSC) osteogenesis and supported sprouting angiogenesis and network formation.
Læs mere »
Work to start on big new housing site in Telford next year - report to councillorsA major housing development is due to get underway in Telford next year, a report to council leaders says.
Læs mere »